Neuronal cell adhesion molecule regulating neural systems underlying addiction.


Journal

Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700

Informations de publication

Date de publication:
03 2019
Historique:
received: 28 08 2018
revised: 18 10 2018
accepted: 19 10 2018
pubmed: 15 12 2018
medline: 21 8 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

The human NRCAM gene is associated with polysubstance use. Nrcam knockout mice do not acquire a preference for addictive substances. We aimed to elucidate the role of Nrcam in specific neural circuits underlying congenital preference for substances and the acquisition of addiction. We analyzed gene expression patterns of neural molecules to find a common addiction pathway dependent on Nrcam function. We examined monoaminergic, glutamatergic, and GABAergic systems in the brains of Nrcam knockout mice following treatment with methamphetamine (METH) or saline (SAL) using micro-array gene expression analysis, which was replicated using TaqMan gene expression analysis. To find a common addiction pathway, we examined similarities and differences between the expression patterns of molecules in METH-treated mice and in Nrcam knockout mice treated with cocaine (COC). Glutaminase expression in brain was reduced in Nrcam heterozygous mice after METH and COC treatment, consistent with our previous study. Metabotropic glutamate receptor 2 expression was reduced in Nrcam heterozygous mice that received either METH or COC treatment. Several other molecules could act in independent addiction pathways involving METH or COC. We also found that GABA receptor subunit g2 expression was reduced in Nrcam heterozygous mice that underwent SAL treatment, and that METH treatment attenuated this reduction. Nrcam differentially regulates glutamatergic and GABAergic molecules in naive brains and in brains of animals with acquired addiction. Elucidating the complex neural mechanisms underlying polysubstance use will uncover biological features of addiction and may contribute to the development of effective pharmaceutical treatments.

Identifiants

pubmed: 30549257
doi: 10.1002/npr2.12038
pmc: PMC7292301
doi:

Substances chimiques

Cell Adhesion Molecules 0
Central Nervous System Stimulants 0
Nrcam protein, mouse 0
Receptors, GABA 0
Methamphetamine 44RAL3456C
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10-16

Informations de copyright

© 2018 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Références

Eur J Pharmacol. 2016 Jun 5;780:129-35
pubmed: 27018393
Psychopharmacology (Berl). 2009 Jun;204(2):361-73
pubmed: 19189082
Int J Neuropsychopharmacol. 2019 Jan 1;22(1):1-9
pubmed: 29788422
Pharmacol Biochem Behav. 2017 Oct;161:13-21
pubmed: 28870523
Front Neurosci. 2015 May 20;9:176
pubmed: 26041984
J Cell Biol. 2001 Sep 17;154(6):1259-73
pubmed: 11564762
Psychiatry Investig. 2012 Dec;9(4):400-7
pubmed: 23251206
Neurochem Res. 2017 Mar;42(3):846-857
pubmed: 28012058
Neuropharmacology. 2017 Mar 15;115:128-138
pubmed: 26987983
Trends Pharmacol Sci. 2018 Aug;39(8):710-732
pubmed: 29903580
J Neurosci. 2003 Apr 15;23(8):3531-7
pubmed: 12716962
Neuropsychobiology. 2014;69(3):154-8
pubmed: 24776921
Neuropsychopharmacol Rep. 2019 Mar;39(1):10-16
pubmed: 30549257
Arch Pharm Res. 2017 Apr;40(4):403-428
pubmed: 28243833
PLoS One. 2012;7(1):e29369
pubmed: 22253714
Int Rev Neurobiol. 2015;120:41-83
pubmed: 26070753
Int Rev Neurobiol. 2014;116:251-73
pubmed: 25172478
Neuropsychopharmacology. 2006 Mar;31(3):572-84
pubmed: 16123759
Addict Biol. 2014 May;19(3):343-53
pubmed: 22780223
Curr Neuropharmacol. 2015;13(6):815-8
pubmed: 26630959
Alcohol. 2018 Feb;66:45-53
pubmed: 29156239
J Cell Biol. 1992 Sep;118(5):1259-70
pubmed: 1512296
Pharmacol Biochem Behav. 2017 Dec;163:74-82
pubmed: 29024680
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16963-8
pubmed: 24082084
Neurotherapeutics. 2017 Jul;14(3):687-697
pubmed: 28324454
Addict Biol. 2018 Jan;23(1):165-181
pubmed: 28271626
Int J Neuropsychopharmacol. 2017 Oct 1;20(10):797-812
pubmed: 28605494

Auteurs

Hiroki Ishiguro (H)

Department of Neuropsychiatry and Clinical Ethics, University of Yamanashi, Chuo, Japan.

Kunio Miyake (K)

Department of Health Sciences, University of Yamanashi, Chuo, Japan.

Koichi Tabata (K)

Department of Neuropsychiatry and Clinical Ethics, University of Yamanashi, Chuo, Japan.

Chiaki Mochizuki (C)

Department of Neuropsychiatry and Clinical Ethics, University of Yamanashi, Chuo, Japan.

Takeshi Sakurai (T)

Medical Innovation Center, Kyoto University, Kyoto, Japan.

Emmanuel S Onaivi (ES)

Department of Biology, William Paterson University, Wayne, New Jersey.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH